Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Sponsor: Aperta Biosciences, LLC
Summary
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to its vehicle control, and to establish that the therapeutic is safe and generally well tolerated by patients.
Official title: Vision and Inflammation Study Testing Anti-acarid Therapeutics (VISTA-1): A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-11-01
Completion Date
2026-04
Last Updated
2025-12-16
Healthy Volunteers
No
Conditions
Interventions
APT-001 topical ophthalmic ointment (spinosad)
APT-001 topical ophthalmic ointment, administered once daily
Vehicle control for APT-001 topical ophthalmic ointment
Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
Locations (2)
Dr. Rudy Gutierrez Diaz Sede Central
Guatemala City, Guatemala
EyeScan, Imágenes Diagnósticas Oculares, S. A.
Guatemala City, Guatemala